Skip to content

Compare

Foundayo vs Saxenda

Quick read · 5 min

Last reviewed: September 2026Based on 2 clinical trialsEvery claim linked to source

Foundayo (orforglipron, daily pill) and Saxenda (liraglutide, daily injection) are both approved for weight loss in the United States. No head-to-head trial has compared these two drugs. The figures below come from separate trials, each with its own participants, length and comparison group.

At a glance

Foundayo and Saxenda compared on form, trial results, cost and reported side effects
 FoundayoSaxenda
FormDaily pillDaily injection
How oftenOnce-daily pill — no injection, no fasting, no food timingDaily injection
Weight loss in trialsUp to 12.4% — ATTAIN-1 (72 weeks)Up to 8% — SCALE Obesity and Prediabetes (56 weeks)
FDA approved20262014
Made byEli LillyNovo Nordisk
How it worksA small-molecule (non-peptide) GLP-1 receptor agonist.A GLP-1 analogue with a half-life of approximately 13 hours (requiring daily injection).
Monthly cost, self-pay$149–$349/mo$1,000–$1,349/mo
Most reported reactionNausea 33% (ATTAIN-1)Nausea 40% (SCALE Obesity and Prediabetes)

Every figure in this table is read from the same trial and label records used everywhere else on this site.

Weight loss in each drug's main trial

No head-to-head trial has compared these two drugs.

Foundayo(orforglipron)12.4%

ATTAIN-1 (72 weeks)

Saxenda(liraglutide)8%

SCALE Obesity and Prediabetes (56 weeks)

In clinical trials, participants taking orforglipron lost on average up to 12.4% of their starting body weight, and participants taking liraglutide lost on average up to 8%. Those numbers come from two different studies: ATTAIN-1 enrolled 3,127 adults with obesity or overweight with comorbidities, no type 2 diabetes over 72 weeks against placebo, while SCALE Obesity and Prediabetes enrolled 3,731 adults with obesity or overweight with comorbidities over 56 weeks against placebo. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.

Monthly cost, self-pay

The bar spans the range in each drug's price record — lowest listed price to highest.

Foundayo$149–$349/mo

$149/month self-pay at the lowest dose, up to $349/month at the highest dose via LillyDirect. $25/month with the commercial insurance savings card. Medicare Part D coverage expected from July 2026 at ~$50/month.

Saxenda$1,000–$1,349/mo

Brand (Saxenda) ~$1,000–$1,349/month. Generic liraglutide is typically $135–$200 less than brand.

Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Foundayo: $149–$349/month. Saxenda: $1,000–$1,349/month. Insurance, dose and pharmacy all change both figures.

Side effects reported in the trials

Both trials reported 4 reactions in common. Each rate is the percentage of participants who reported it in the trial named beside it, so the two columns are not from the same study.

Nausea
Foundayo · ATTAIN-133%
Saxenda · SCALE Obesity and Prediabetes40%
Diarrhoea
Foundayo · ATTAIN-115%
Saxenda · SCALE Obesity and Prediabetes21%
Vomiting
Foundayo · ATTAIN-119%
Saxenda · SCALE Obesity and Prediabetes16%
Constipation
Foundayo · ATTAIN-118%
Saxenda · SCALE Obesity and Prediabetes19%

A rate is the share of trial participants who reported that reaction, not a prediction for any one person.

How they differ in practice

How you take it

  • FoundayoOnce-daily oral tablet. No food or water restrictions.
  • SaxendaOnce-daily subcutaneous injection

Dose build-up

  • Foundayo3 mg → 6 mg → 12 mg → 36 mg, escalated over several months
  • Saxenda0.6 mg → 3.0 mg, escalated over 4 weeks

Where a drug is not listed here, its prescribing information sets out its own dose steps.

How soon it acts

  • FoundayoAppetite changes typically within the first 4 weeks; meaningful weight loss by 12–16 weeks
  • SaxendaEffects visible within 4–8 weeks; maximum benefit typically by 56 weeks

Heart and metabolic findings

  • FoundayoCardiovascular outcomes data pending.
  • SaxendaThe LEADER trial (type 2 diabetes) showed cardiovascular benefit.

As stated in each drug’s trial record — not a claim about which drug protects the heart more.

Other findings recorded

  • FoundayoNo food or water restrictions — take any time of day; available at $149/month self-pay (lowest dose) or $25/month with commercial insurance
  • SaxendaApproved for adolescents aged 12 and over (SCALE teens programme); generic liraglutide now available (Teva, August 2025) — reducing out-of-pocket cost

If you stop taking it

  • FoundayoNo withdrawal trial has been published for Foundayo.
  • SaxendaWeight regain after stopping is expected, as with other GLP-1 drugs.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Next step most people take

Built with agentic AI tools and not a substitute for medical advice

Last reviewed:

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.